



2014-12-30

PRESS RELEASE

Publication of change in the total number of shares and votes in Oasmia

December 30, 2014

The total number of shares and votes in Oasmia Pharmaceutical AB (publ) amounts to 97,858,144 as of December 30, 2014. The increase in the number of shares is attributable to the new share issue with preferential rights for current shareholders carried out in November/December 2014, which comprised 9,785,814 shares. The share issue was registered in its entirety with the Swedish Companies Registration Office on December 15, 2014.

A list of the company principal shareholders will be available at www.oasmia.com

For more information, please contact:

Anders Lundin, CFO

Mobile: +46 70 209 63 00

E-mail: anders.lundin@oasmia.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops a new generation of drugs within human and veterinary oncology. The product development aims to manufacture novel formulations based on well-established cytostatics which, compared to current alternatives, show improved properties, a reduced side-effect profile and an expanded therapeutic area. Product development is based on in-house research within nanotechnology and proprietary patents. Oasmia Pharmaceutical AB's shares, ISIN SE0000722365, are listed on NASDAQ Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

Information is also available at www.oasmia.com, www.nasdaqomxnordic.com, www.boerse-frankfurt.de and twitter.com/oasmia

"Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 8.50 CET on December 30, 2014."